Eric Wickramasekara was an undergrad at MIT when he came up with the idea for a cloud-based Crispr design tool to help scientists. Eight years later, Regeneron, Gilead and hundreds of other companies use its collaborative R&D software, and the company boasts a roaster of investors that includes Andreessen Horowitz, Benchmark, Menlo Ventures, Thrive Capital, and Y Combinator. As many customers rush to come up with vaccines and treatments for Covid-19, Benchling is on call as needed—but has stopped pushing software updates to those whose projects require total lockdown.
Read more about the Next Billion Dollar Startups on Forbes: https://www.forbes.com/sites/amyfeldman/2020/05/28/next-billion-dollar-startups-2020/#2b4947d03f9f
Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1
Forbes newsletters: https://newsletters.editorial.forbes.com
Forbes on Facebook: http://fb.com/forbes
Forbes Video on Twitter: http://www.twitter.com/forbes
Forbes Video on Instagram: http://instagram.com/forbes
More From Forbes: http://forbes.com
Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.
How A Tool For Scientists Became A Billion-Dollar Opportunity | Forbes